PTX Media related, page-777

You would think, given the company is tapping its owners for extra cash to fund its progress, that the owners of the company might be updated before a conference presentation is given to industry participants. CellPryme is one of the blue chip oncology assets 100% owned by the company, but all the owners have been told so far is that is synergises CellPryme-M but is otherwise "undisclosed". This has been labelled as an "unveiling" and given that the CellPryme-M announcement was price sensitive, it would logically follow that CellPryme-A as part of the CellPryme asset, is price sensitive as well.

If not announced during trading today, I think it will be an after market announcement this afternoon to comply and definitely before the market opens on Friday. It is entirely different to exemptions for trade secrets, the existence of the product and what they say it can (may) do and why it is better than other products is not a trade secret, it's entirely relevant information for investors and must be released to the market before being presented to the industry assuming it is treated the same as CellPryme-M.